6月7日,CDE官网公示显示,默沙东提交的帕博利珠单抗注射液(皮下注射)上市申请获得正式受理,这是首款在国内申报上市的皮下注射PD-1抗体。当我们谈论抗癌药,谈的不仅是疗效和价格,还有治疗效率的革命性提升。默沙东这款被业内称为“K药皮下版”的创新制剂,将传统静脉输注的30-60分钟治疗时间,压缩到了短短2分钟。MK-3475A皮下注射制剂由帕博利珠单抗与Berahyaluronidasealfa(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.